APOE and Alzheimer’s Risk

What genetic testing can and can’t tell you

APOE is a well-established genetic risk factor for late-onset Alzheimer’s disease. It is not a diagnosis, and it cannot tell you what will happen to you.

This article explains how to think about APOE testing as part of a preventive, data-informed approach to brain health, and how we frame results at NiaHealth.

Late-onset Alzheimer’s disease

Alzheimer’s disease is a progressive brain disease and the most common cause of dementia. Dementia is an umbrella term for symptoms that affect thinking and interfere with daily life, such as changes in memory, judgment, language, or problem-solving. Alzheimer’s is one specific disease process that can lead to these symptoms.

Most people are diagnosed with Alzheimer’s disease after age 60 to 65. This is known as late-onset Alzheimer’s disease. The biological changes linked to Alzheimer’s, including amyloid plaques and tau tangles in the brain, begin quietly long before symptoms appear. These changes can be present for many years before they affect day-to-day life.

Knowing that Alzheimer’s disease has a long, silent phase has changed how researchers and clinicians think about prevention. If the disease process begins so early, there may be opportunities to intervene before symptoms develop. For people thinking proactively about brain health, understanding baseline risk of developing Alzheimer’s is often the starting point.

This is where genetics, specifically the APOE gene, enters the conversation.

Alzheimer’s risk is complex

Late-onset Alzheimer’s disease is not caused by a single “Alzheimer’s gene,” and its biology is not yet fully understood. What we do know is that risk builds gradually over time and is influenced by many different factors.

Age is the strongest risk factor, followed by sex. Risk increases steadily with age, and women are affected more often than men. Alzheimer’s disease risk is also influenced by biology, lifestyle, and environment over the course of a lifetime.

No single factor acts in isolation. Each person carries an individual risk profile that reflects how these influences combine over decades.

Genetics is part of this risk picture, but it is only one part. For people with a parent or sibling affected by Alzheimer’s disease, genetics can feel especially personal. Even when someone understands that risk is not destiny, family history often carries emotional weight.

From a scientific standpoint, late-onset Alzheimer’s disease is influenced by many genes, each with a small effect. Researchers are still learning how these genetic factors interact with one another and with health and lifestyle over time.

Among all the genes studied so far, one stands out.

Understanding APOE

APOE (pronounced “ay-poh-ee”) is a gene associated with risk for late-onset Alzheimer’s disease. There are three common versions of APOE called e2, e3, and e4.

We inherit our genes in pairs, one copy from each biological parent. As a result, everyone carries two copies of the APOE gene, leading to six possible combinations:

• e2/e2
• e2/e3
• e2/e4
• e3/e3
• e3/e4
• e4/e4

Research has shown that e4 is linked to a higher risk of developing late-onset Alzheimer’s disease and is associated with the earlier development of symptoms. e3 is the most common version and is generally considered risk-neutral. e2 is less common and is associated with a lower risk.

When it comes to APOE, the most important takeaway is this: APOE can shift risk, but it does not determine outcomes. Many people who carry e4 never develop Alzheimer’s disease, and an estimated 40–50% of people diagnosed with Alzheimer’s disease do not carry e4.

As a NiaHealth genetic counsellor puts it:

“APOE is neither sufficient nor necessary when it comes to Alzheimer’s disease. It influences risk, but it is only one piece of a much larger and more complex picture.”

How is APOE tested?

APOE testing is a genetic test that looks at which versions of the APOE gene you carry. It is performed using a saliva or cheek swab sample. In the laboratory, DNA is extracted and analyzed using a method called genotyping. While APOE can also be assessed using other laboratory methods, genotyping directly examines the gene itself and is considered the gold standard.

Most people carry two copies of e3, which is not associated with increased genetic risk. About 20 to 25% of the population carries one copy of e4, most often as e3/e4, which is associated with higher risk for late-onset Alzheimer’s. A much smaller group carries e4/e4, which is associated with the highest genetic risk among common APOE versions.

APOE testing does not diagnose Alzheimer’s disease, and it cannot tell you whether you will or will not develop it.

Rather, your APOE result can help place you into a broad inherited risk category, such as lower, average, or higher risk. When looked at together with your overall health picture, this information may be useful for prevention planning.

In a structured preventive health setting, APOE genotyping can add meaningful context when results are interpreted carefully and not viewed in isolation.

A note on early-onset Alzheimer’s disease

Early-onset Alzheimer’s disease refers to symptoms that begin before age 60 to 65. It is uncommon and accounts for fewer than 5 percent of all Alzheimer’s cases.

In rare families, early-onset Alzheimer’s disease is caused by a single inherited genetic change in genes such as APP, PSEN1, or PSEN2. These forms follow a clear inheritance pattern and typically lead to symptoms at younger ages.

APOE testing does not assess these rare genes. It is designed to provide information about risk for late-onset Alzheimer’s disease only.

If you or a close family member developed Alzheimer’s symptoms at a young age, genetic counselling and medical evaluation through the public healthcare system are recommended.

What should you do with your APOE result?

There is growing evidence that many Alzheimer’s cases may be preventable or delayable, particularly when risk-reduction strategies begin earlier in life. While prevention science is still evolving, the overall message from large, long-term studies is encouraging.

In the Chicago Health and Aging Project, researchers found that people who consistently engaged in multiple healthy lifestyle behaviours had a substantially lower risk of developing Alzheimer’s disease. Importantly, this benefit was seen even among people who carried the APOE e4 variant. Genetic risk did not eliminate the benefits of healthy behaviours.

APOE results may help you decide how early and how strongly to focus on prevention strategies. When it comes to which strategies to choose, we know that good heart health supports good brain health. Many of the strongest prevention signals for Alzheimer’s disease overlap with cardiovascular, metabolic, and cognitive health.

The strongest areas for prevention

The strongest evidence for reducing Alzheimer’s risk clusters around a small number of well-studied areas that influence brain health over time. Key areas include:

• blood pressure control
• diabetes prevention and management
• regular physical activity
• avoiding smoking
• hearing assessment and treatment when needed
• treating depression and supporting mental health
• maintaining social connection
• cognitive engagement and lifelong learning

These areas closely reflect the findings of the 2024 Lancet Commission on dementia prevention, which identifies modifiable risk factors across the life course. In addition to well-established factors such as lower education, hearing loss, hypertension, smoking, obesity, depression, physical inactivity, diabetes, and social isolation, the Commission’s latest report also highlights high midlife LDL cholesterol and untreated vision loss as contributors to dementia risk.

Taken together, the Commission estimates that addressing these 14 modifiable risk factors across the lifespan could potentially prevent or delay a substantial proportion of dementia cases worldwide.

The key takeaway is this: these strategies matter regardless of APOE status. While APOE can shift baseline risk, everyday health choices remain powerful drivers of brain health across all genotypes.

What APOE testing can’t do

APOE testing cannot tell you:

• whether you will develop Alzheimer’s disease
• when symptoms might begin
• whether current memory changes are due to Alzheimer’s
• which type of dementia might occur
• whether a specific supplement or diet will work for you

If you are experiencing cognitive symptoms now, genetic risk testing is not the right next step. A medical evaluation through your primary care provider is recommended.

How we frame APOE at NiaHealth

At NiaHealth, APOE testing is not used to diagnose disease or predict outcomes. We treat it as one piece of information that can help inform how someone thinks about their brain health over time.

We interpret results in the context of your overall health picture, including family history, age, sex, cardiometabolic markers, lifestyle, sleep, hearing, and personal goals. Because your DNA does not change, APOE testing does not need to be repeated. Instead, we view APOE as information that can be revisited over time, as health factors evolve and scientific understanding continues to advance.

Our focus is on sharing evidence-based information that supports informed, realistic choices. We aim to empower members to take ownership of their health in a responsible, data-informed way.

We also talk about emotional readiness up front. APOE is a risk test that can carry emotional weight. For some people, it is motivating. For others, it may not be helpful right now. Choosing not to test is a valid decision.

Is APOE testing right for you?

People may choose testing if they:

• have family members with late-onset Alzheimer’s and want clearer context
• are already prevention-focused and want guidance on where to focus
• prefer having information and understand how it fits into their overall risk profile
• want to think about brain health earlier than the traditional healthcare timeline

People may choose not to test if they:

• feel anxious or not emotionally ready
• worry they may interpret results as destiny
• are hoping for certainty
• are dealing with active memory concerns

A simple self-check many people find helpful is: Will this information help me make practical changes or priorities around my brain health, or will it mostly add worry?

APOE testing at NiaHealth

We offer clinical-grade APOE genotyping through a Canadian medical laboratory, genetic counselling is available before and after testing.

The process includes:

• Pre-test counselling to review benefits, limitations, and whether testing fits your goals
• At-home cheek swab, with prepaid return
• Results review and post-test counselling, focused on interpretation, emotional support, and helping members decide on practical next steps that fit their priorities

What to take away

APOE has helped researchers better understand Alzheimer’s disease risk at the population level, but for any individual, it is only a limited predictor. When used carefully and interpreted in context, APOE can still be a helpful source of information for people who want to think about brain health earlier and more intentionally.

At NiaHealth, our role is not to direct decisions, but to share clear, evidence-based information and support people as they decide what feels right for them.

If you are unsure whether APOE testing is a good fit, that question is exactly what pre-test counselling is designed to explore.